Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38+0.01 (+0.73%)
Close on Nov 18, 2026Market cap $249.88MP/E –Yield –
Century Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Century Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$88.09M. For fiscal 2025 it was -$104.72M. The highest annual figure on record is -$16.55M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$104.72M | – |
| FY2024 | Dec 31, 2024 | -$110.29M | – |
| FY2023 | Dec 31, 2023 | -$102.08M | – |
| FY2022 | Dec 31, 2022 | -$16.55M | – |
| FY2021 | Dec 31, 2021 | -$133.97M | – |
| FY2020 | Dec 31, 2020 | -$51.09M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.85M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.91M | – |
| Q1 FY2025 | Mar 31, 2025 | -$35.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$23.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.21M | -141.4% |
| Q4 FY2022 | Dec 31, 2022 | -$29.18M | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$36.01M | – |
| Q1 FY2022 | Mar 31, 2022 | $82.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$41.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$39.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.12M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.73M | – |
See a number that looks wrong?